Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.46 |
| ▸ | CBX7 | O95931 | 1/20 | 0.46 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.46 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.46 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284498 | 0.85 | PGR (0.64) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL318631 | 0.84 | DAO (0.55) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL11506760 | 0.82 | DAO (0.56) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL10284697 | 0.80 | LMNA (0.64) | HTR7LMNAHTR1AMAPK1MEN1 | |
| SCHEMBL11708301 | 0.80 | DAO (0.57) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL11703773 | 0.79 | DAO (0.59) | PGRDAOB3GNT2CBX7CDYL2 | |
| SCHEMBL6910220 | 0.78 | PGR (0.72) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL9725376 | 0.78 | DAO (0.51) | PGRDAOCBX7CDYL2CDYL | |
| Hydrochloric Acid SCHEMBL9725385 | 0.77 | MPO (0.50) | PGRDAOCBX7CDYL2CDYL | |
| SCHEMBL9725443 | 0.76 | DAO (0.52) | PGRDAOB3GNT2CBX7CDYL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8691836-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | PGR 440/4885DAO 697/4885B3GNT2 1945/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | PGR 440/4885DAO 697/4885B3GNT2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.